Abstract
CADTH recommends that Xydalba should be reimbursed by public drug plans for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA), only if certain conditions are met. Xydalba should only be covered to treat patients who have known or suspected MRSA ABSSSI and are unlikely to adhere to outpatient antibiotic treatment or prolonged hospitalization. Xydalba should be negotiated so that it does not exceed the drug program cost of treatment with the least costly IV antibiotic reimbursed for the treatment of known or suspected MRSA ABSSSI.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call